Identification of Anti- and Anti- Compounds With Potential Distinctive Structural Scaffolds From an HD-PBL Using Phenotypic Screens in Amoebae Host Models
Overview
Authors
Affiliations
Tubercular and are the causative agents of potentially fatal respiratory diseases due to their intrinsic pathogenesis but also due to the emergence of antibiotic resistance that limits treatment options. The aim of our study was to explore the antimicrobial activity of a small ligand-based chemical library of 1255 structurally diverse compounds. These compounds were screened in a combination of three assays, two monitoring the intracellular growth of the pathogenic bacteria, and , and one assessing virulence of . We set up these assays using two amoeba strains, the genetically tractable social amoeba and the free-living amoeba . In summary, 64 (5.1%) compounds showed anti-infective/anti-virulence activity in at least one of the three assays. The intracellular assays hit rate varied between 1.7% ( = 22) for and 2.8% ( = 35) for with seven compounds in common for both pathogens. In parallel, 1.2% ( = 15) of the tested compounds were able to restore growth in the presence of spiked in a lawn of food bacteria. We also validated the generality of the hits identified in the - anti-infective screen using the - host-pathogen model. The characterization of anti-infective and antibacterial hits in the latter infection model revealed compounds able to reduce intracellular growth more than 50% at 30 μM. Moreover, the chemical space and physico-chemical properties of the anti- hits were compared to standard and candidate (Mtb) drugs using ChemGPS-NP. A principle component analysis identified separate clusters for anti- and anti- hits unveiling the potentially new physico-chemical properties of these hits compared to standard and candidate drugs. Our studies underscore the relevance of using a combination of low-cost and low-complexity assays with full 3R compliance in concert with a rationalized focused library of compounds to identify new chemical scaffolds and to dissect some of their properties prior to taking further steps toward compound development.
Boujut M, Heritier M, Gouiller A, Suess C, Scapozza A, De Smedt T J Med Chem. 2025; 68(4):4059-4078.
PMID: 39855635 PMC: 11873987. DOI: 10.1021/acs.jmedchem.4c01691.
Lefrancois L, Nitschke J, Wu H, Panis G, Prados J, Butler R mSystems. 2024; 9(2):e0132623.
PMID: 38270456 PMC: 10878075. DOI: 10.1128/msystems.01326-23.
Ayon N Metabolites. 2023; 13(5).
PMID: 37233666 PMC: 10220967. DOI: 10.3390/metabo13050625.
High-Throughput Screen for Inhibitors of Virulence Using a Co-Culture Surrogate Host Model.
Woods A, Parker D, Glick M, Peng Y, Lenoir F, Mulligan E ACS Omega. 2022; 7(6):5401-5414.
PMID: 35187355 PMC: 8851646. DOI: 10.1021/acsomega.1c06633.
Role of LrrkA in the Control of Phagocytosis and Cell Motility in .
Bodinier R, Sabra A, Leiba J, Marchetti A, Lamrabet O, Ayadi I Front Cell Dev Biol. 2021; 9:629200.
PMID: 33763419 PMC: 7982419. DOI: 10.3389/fcell.2021.629200.